The global gamma knife market size was valued at USD 364.6 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5.0% from 2022 to 2030. The increasing prevalence of neurological disorders and brain tumors, rapid adoption of gamma knife surgeries as an effective treatment option, continuous technological advancements, and evolution of minimally invasive surgery options are expected to fuel the market growth. However, higher costs of treatments and installation of machinery, fluctuating reimbursement rates, and a dearth of skilled professionals are factors expected to hamper the market growth.
The COVID-19 pandemic has negatively impacted radiology practices across the globe. A 50% reduction in elective surgeries was witnessed within the first month of the pandemic. Hospitals are mainly focusing on tackling COVID-19 cases, which minimized their capacity to undertake critical radiotherapy operations. Reduction in raw material production, halt in logistics, reduced sales of newer systems, and national lockdowns were other reasons for the drop in market size in 2020.
The global burden of neurological disorders is measured by the absolute number of Disability-adjusted Life Years (DALYs), which continues to increase. The prevalence of major neurological disorders is increasing owing to the rising geriatric population. According to the American Cancer Society, brain tumor is considered the 8th most common type of cancer and the 3rd most common cause of cancer deaths in the age group of 40 and above. As the population is aging and growing, the demand for treatment and rehabilitation for neurological diseases is expected to increase significantly, hence positively impacting the growth of the market.
Gamma knife surgery is a computer-guided treatment, which is painless and used to deliver strong focused radiation beams to treat brain tumors and lesions, arteriovenous malformations, acoustic neuroma, tremors, and trigeminal neuralgia. For instance, Leksell Gamma Knife Icon, by a key market player Elekta AB (publ), uses single or fractionated frame-based or frameless treatments with more precision and accuracy for brain tumors, cancer, and other neurological diseases.
The malignant tumors segment held the largest revenue share of over 45.0% in 2021. The benign tumors segment is expected to grow over the forecast period owing to the increasing prevalence of meningioma. On the basis of indication, the market is segmented into malignant tumors, benign tumors, vascular disorders, functional disorders, and ocular brain tumors.
According to the American Society of Clinical Oncology (ASCO), currently, 700,000 patients are suffering from brain tumors. In 2021, around 24,530 adults-13,840 males and 10,690 females in the U.S. are expected to be diagnosed with the primary type of malignant tumor in the spinal cord and brain. In addition, around 3,460 children under the age of 15 years are expected to be diagnosed with brain tumors. Around 18,600 adults-around 10,500 males and 8,100 females-are likely to die due to these types of cancer in the coming year, thereby augmenting the segment growth.
In 2021, Asia Pacific held the largest revenue share of over 35.0%. An increase in the prevalence of neurological diseases, a rise in healthcare expenditures, and growth in the accessibility of gamma knife surgeries are some of the key factors expected to drive the market in APAC over the forecast period.
The adoption of gamma knife surgery systems is reported to be increasing in North America. Moreover, various clinical studies are being undertaken for exploring the applications of gamma knife radiotherapy in treating essential tremors, such as Parkinson’s and glioblastoma. Thus, the expansion of applications of gamma knife radiotherapy to other treatment areas is expected to further drive the market.
Key market players operating in the market are involved in novel product launches, joint ventures, product innovation, collaboration and partnerships, and mergers & acquisitions to expand their global reach. For instance, in May 2020, Elekta launched Leksell Gamma Knife Lightning, which was the only fully integrated automated treatment planning solution for gamma knives that enables plan-optimization based on parameters such as beam on-time constraints. Some prominent players in the global gamma knife market include:
Elekta AB
Varian Medical Systems
Huiheng Medical, Inc.
MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
Akesis Inc.
Report Attribute |
Details |
The market size value in 2022 |
USD 424.7 million |
The revenue forecast in 2030 |
USD 626.4 million |
Growth rate |
CAGR of 5.0% from 2022 to 2030 |
The base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segment Covered |
Indication, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; China; India; Japan; South Korea; Mexico; Brazil; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Elekta AB; Varian Medical Systems; Huiheng Medical, Inc.; MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.; Akesis Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail of customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global gamma knife market report based on indication and region:
Indication Outlook (Revenue, USD Million, 2018 - 2030)
Malignant Tumors
Benign Tumors
Vascular Disorders
Functional Disorders
Ocular Diseases
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
China
Japan
India
South Korea
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
UAE
b. The global gamma knife market size was estimated at USD 364.6 million in 2021 and is expected to reach USD 424.7 million in 2022.
b. The global gamma knife market is expected to grow at a compound annual growth rate of 5.0% from 2022 to 2030 to reach USD 626.4 million by 2030.
b. Asia Pacific dominated the gamma knife market with a share of 40.1% in 2021. This is attributable to a high incidence of brain tumors, rising awareness amongst healthcare professionals regarding noninvasive treatment alternatives.
b. Some key players operating in the gamma knife market include Elekta AB, Varian Medical Systems, Cyber Medical Corporation, ET Medical Group, GE Healthcare, Masep Infini Global Inc., and Huiheng Medical, Inc.
b. Key factors that are driving the gamma knife market growth include the rapid surge in the global incidence of neurological diseases such as brain tumors and epilepsy, rising adoption of the instruments in surgical centers, and product launch.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.